Development of APOL1 mouse platform for focal segmental glomerulosclerosis and chronic kidney disease advances

Active Project Grant Awarded Last action

Award ID
HT94252410205
Recipient
Awarding agency
Obligated
$1,835,034

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 59% complete
Place of performance
West Lafayette, IN, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The U.S. Department of Defense, through its Military Medical Research and Development program (CFDA 12.420), awarded a $1,835,034 project grant to Inotiv, Inc. to develop an APOL1 mouse platform for research into focal segmental glomerulosclerosis and chronic kidney disease. The grant, which runs from June 2024 to June 2028, will support Inotiv's efforts to advance biomedical research in these areas of military medical importance. As a contract research organization, Inotiv has extensive experience working with federal agencies on a variety of preclinical and clinical research services, including toxicology studies, bioanalytical assays, and specialized equipment for biomedical research. This award demonstrates Inotiv's expertise in providing innovative solutions to address critical health challenges facing the military and the broader population.

Quick answers

Who received award HT94252410205?

HT94252410205 was awarded to Inotiv, Inc. by Defense Health Agency (Department of Defense) on June 15, 2024.

How much is award HT94252410205 worth?

$1,835,034 has been obligated on HT94252410205.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login